Back

Very low-dose recombinant factor VIIa for optimized treatment of cardiovascular patients at high risk of hemorrhage

27 August 2016 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Antithrombotics in daily clinical practice Thrombosis and coagulation ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor Alexander Assmann

Duesseldorf (Germany)

9 More presentations in this session

Presentation thumbnail
Equal safety of rivaroxaban and vitamin K antagonists with regard to the risk of intracranial- and gastrointestinal bleeding in patients with venous thromboembolism - A Danish nationwide study
Ms C. Sindet-Pedersen (Hellerup, DK)
Abstract
Presentation thumbnail
Risk of venous thromboembolism recurrences in patients who continued versus discontinued rivaroxaban therapy after an initial six-month therapy
Doctor C. Crivera (Raritan, NJ, US)
Abstract Slides Video
Presentation thumbnail
Efficacy and bleeding risk of newer anticoagulants compared to conventional treatment in patients with chronic kidney disease- a meta analysis of randomized controlled trials
Assistant Professor K. Prudhvi (Tucson, US)
Abstract Slides Video
Presentation thumbnail
Management of acute venous thromboembolism in Europe - follow-up data at 1 month from the PREFER in VTE registry
Doctor A. Cohen (London, GB)
Abstract Slides Video
Presentation thumbnail
Red blood cell transfusions increase platelet reactivity in patients treated with dual antiplatelet therapy
Miss M. Quillot (Toulouse, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Antithrombotics in daily clinical practice

The Event

Event poster

ESC Congress 2016

27 August - 31 August 2016

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources